title: Selenitetriglycerides-Redox-active agents.
abstract: BACKGROUND
  Human prostate cancer (hPCa) is the most commonly diagnosed cancer in elderly men and is the second leading cause of male cancer death. Data from epidemiological, eco-environmental, nutritional prevention and clinical trials suggest that selenium Se(IV) can prevent prostate cancer. Selol, a new organic semisynthetic derivative of Se(IV), is a mixture of selenitetriglycerides. This mixture is non-toxic and non-mutagenic, and after po treatment - 56-times less toxic (in mice) than sodium selenite. It exhibits strong anti-cancer activity in vitro in many cancer cell lines and can overcome the cell resistance to doxorubicin. Selol seems a promising compound for prostate cancer therapy.
  
  
  METHODS
  The aim of the present study is the evaluation of Selol's influence on intracellular redox state (Eh) of prostatic tumors and the liver in androgen-dependent hPCa-bearing mice, and extracellular redox state in serum of these mice.
  
  
  CONCLUSIONS
  The anticancer activity of Selol involves perturbation of the redox regulation in the androgen dependent hPCa (LNCaP) cells, but not in healthy cells. After Selol treatment, intracellular Eh has increased in tumors from -223 mV to -175 mV, while in serum it has decreased (-82 mV vs -113 mV). It shows significant changes Eh in the extra- and intracellular environment. The difference decreases from 141 mV to 62 mV. The changes suggest that a tumor cell was probably directed toward apoptosis. This is exemplified in a significant decrease in cancer tumor mass by approx. 17% after the three weeks of Selol administration.
authors.affiliation: Department of Bioanalysis and Drugs Analysis, Medical University of Warsaw, Warszawa, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Flis
authors.affiliation: Department of Bioanalysis and Drugs Analysis, Medical University of Warsaw, Warszawa, Poland; Department of Pharmaceutical Chemistry, National Medicines Institute, Warszawa, Poland. Electronic address: piotr.suchocki@wum.edu.pl.
authors.forename: Piotr
authors.initials: P
authors.lastname: Suchocki
authors.affiliation: Department of Bioanalysis and Drugs Analysis, Medical University of Warsaw, Warszawa, Poland.
authors.forename: Monika Anna
authors.initials: MA
authors.lastname: Królikowska
authors.affiliation: Department of Biochemistry and Clinical Chemistry, Medical University of Warsaw, Warszawa, Poland.
authors.forename: Zofia
authors.initials: Z
authors.lastname: Suchocka
authors.affiliation: Department of Pharmacology, National Medicines Institute, Warszawa, Poland.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Remiszewska
authors.affiliation: Department of Bioanalysis and Drugs Analysis, Medical University of Warsaw, Warszawa, Poland.
authors.forename: Lidia
authors.initials: L
authors.lastname: Śliwka
authors.affiliation: Department of Biochemistry and Biofarmaceuticals, National Medicines Institute, Warszawa, Poland.
authors.forename: Iza
authors.initials: I
authors.lastname: Książek
authors.affiliation: Department of Biochemistry and Biofarmaceuticals, National Medicines Institute, Warszawa, Poland.
authors.forename: Karolina
authors.initials: K
authors.lastname: Sitarz
authors.affiliation: Department of Bioanalysis and Drugs Analysis, Medical University of Warsaw, Warszawa, Poland.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Sochacka
authors.affiliation: The Center of Postgraduate Medical Education, Department of Clinical Cytology, Warszawa, Poland.
authors.forename: Grażyna
authors.initials: G
authors.lastname: Hoser
authors.affiliation: Department of Biochemistry and Biofarmaceuticals, National Medicines Institute, Warszawa, Poland.
authors.forename: Elżbieta
authors.initials: E
authors.lastname: Anuszewska
authors.affiliation: Department of Bioanalysis and Drugs Analysis, Medical University of Warsaw, Warszawa, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Wroczyński
authors.affiliation: Department of Pharmacology, National Medicines Institute, Warszawa, Poland.
authors.forename: Zenon
authors.initials: Z
authors.lastname: Jastrzębski
mesh_terms: D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D003545:Cysteine / Q000378:metabolism; D003553:Cystine / Q000378:metabolism; D005110:Extracellular Space / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D010084:Oxidation-Reduction; D018384:Oxidative Stress / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000188:drug therapy; D012643:Selenium / Q000032:analysis / Q000493:pharmacokinetics; D018036:Selenium Compounds / Q000493:pharmacokinetics / Q000494:pharmacology*; D013438:Sulfhydryl Compounds / Q000032:analysis; D014018:Tissue Distribution; D014280:Triglycerides / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D018036:Selenium Compounds; D013438:Sulfhydryl Compounds; D014280:Triglycerides; C105370:selol; D003553:Cystine; D012643:Selenium; D003545:Cysteine
keywords: LNCaP; Oxidative stress; Redox state; Selenitetriglycerides; Selol